Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (431-440 of 512) with videos related to

Pageof 52
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
Molecular Cancer|June 29, 2026
A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunctionFilippo Gustavo Dall'Olio, Wael Salem Zrafi, Xinran Song, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2021
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control studyCharlotte Cabanié, Samy Ammari, Sophie Hans, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.
JCO Precision Oncology|September 14, 2020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung CancerLaura Mezquita, Aurélie Swalduz, Cécile Jovelet, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2024
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancerIlias Houda, Idris Bahce, Chris Dickhoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni SyndromeLaura Mezquita, Maria Jové, Ernest Nadal, et al.
Pageof 52

Showing results (431-440 of 512) with videos related to

Sort By:
Pageof 52
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
Molecular Cancer|June 29, 2026
A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunctionFilippo Gustavo Dall'Olio, Wael Salem Zrafi, Xinran Song, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2021
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control studyCharlotte Cabanié, Samy Ammari, Sophie Hans, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.
JCO Precision Oncology|September 14, 2020
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung CancerLaura Mezquita, Aurélie Swalduz, Cécile Jovelet, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2024
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancerIlias Houda, Idris Bahce, Chris Dickhoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni SyndromeLaura Mezquita, Maria Jové, Ernest Nadal, et al.
Pageof 52